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ABSTRACT 
Studies evaluating the safety and efficacy of Listex
TM
 P100 to reduce Listeria monocytogenes 
contamination on raw fish were assessed. The material should not present human toxicological problems 
because the bacteriophage P100, used as active principle, is not regarded as harmful to consumers nor to 
organisms other than Listeria spp., and because the fabrication parameters do not include anything 
obvious that might compromise safety. Data of studies considered indicate that Listex
TM
 P100 is 
listericidal on inoculated catfish and salmon samples, but do not allow definitive conclusions on efficacy 
in reducing L. monocytogenes counts on raw fish nor on its impact on L. monocytogenes contamination 
levels in finished product. It was not possible to estimate the potential listeriosis risk reduction by treating 
raw fish with Listex™ P100. The data were not adequate to allow firm conclusions on persistence or 
activity of P100 in stored fish. The proposed use of Listex
TM
 P100 is unlikely to result in emergence of 
reduced susceptibility to biocides and/or resistance to key therapeutic antimicrobials: however, this 
conclusion may need verification. No information was provided on survival of P100 in processing 
wastewater or the environment, or on the potential accumulation of naturally P100 resistant 
L. monocytogenes variants. Pilot and industrial scale studies should consider parameters affecting 
decontaminating efficacy, and should verify that application on raw fish has an impact on reduction of 
L. monocytogenes contamination on the final product. The persistence or activity of P100 as well as 
potential changes in L. monocytogenes counts should be evaluated during fish storage. Tests to investigate 
potential development of resistance or reduced susceptibility to biocides and key therapeutic 
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antimicrobials, following use of Listex
TM
 P100, are recommended. The continuous effectiveness of 
Listex
TM
 P100 against L. monocytogenes and the potential for selection and dominance of strains 
naturally-resistant to P100 should be monitored.  
© European Food Safety Authority, 2012 
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SUMMARY 
Following a request from the European Commission, the Panel on Biological Hazards 
(BIOHAZ Panel) was asked by the European Food Safety Authority (EFSA) to deliver a 
Scientific Opinion on an application dossier submitted by Micreos BV (the Netherlands) for the 
approval of Listex
TM
 P100 for spraying or dipping uses aimed to reduce Listeria monocytogenes 
surface contamination of raw fish. 
The Commission asked EFSA to issue a Scientific Opinion on the assessment of the safety and 
efficacy of Listex
TM
 P100 when used to reduce L. monocytogenes surface contamination of raw 
fish. Specifically, the task was to consider the toxicological safety of the substance, its 
antimicrobial efficacy, the potential emergence of reduced microbial susceptibility to biocides 
and/or resistance to therapeutic antimicrobials linked to the use of the substance, and any risk 
related to the release of the processing plant effluents containing the substance into the 
environment. The assessment was based on the document “Guidelines on the submission of data 
for the evaluation of the safety and efficacy of substances for the removal of microbial surface 
contamination of foods of animal origin intended for human consumption” published by EFSA4. 
Concerning human toxicological safety, the Listex
TM
 P100 preparation should not present 
problems because the bacteriophage P100 used as active principle is not regarded as harmful to 
consumers. Furthermore the Listex
TM
 P100 manufacturing parameters do not include any 
obvious components or steps that might compromise safe use of the preparation. 
The experiments of the two relevant for consideration laboratory studies used to assess the 
efficacy of Listex
TM
 P100 as a decontaminating agent for raw fish were classified as of „low 
strength of evidence‟. Thus their data are indicative of a disinfectant effect that may be 
reproducible in practice but do not allow definitive conclusions on the efficacy of the product in 
reducing naturally occurring low L. monocytogenes counts on raw fish. Results were not 
validated under pilot plant or industrial conditions. Data presented indicated that Listex
TM
 P100 
is listericidal. Reductions were in the range of 1.4 to 3.5 log10 cfu/g on inoculated fresh catfish 
and salmon fillet samples. Limitations of the studies were that only two fish types were tested 
and sample sizes were generally small and with few repetitions. Additionally only a two-strain, 
two-serotype mixture of L. monocytogenes was evaluated, no strains of fish origin were 
included, and lower L. monocytogenes contamination levels, usually expected on fish, were not 
tested. 
Listeria monocytogenes counts showed an upward trend in treated catfish fillets during the  
10-day storage at 4 °C or 10 °C, but not in treated salmon fillets stored for 10 days at 4 °C. It is 
unclear whether these counts were due to total prevention of bacterial growth or to the balance 
between growth and death of bacterial cells. Bacteriophage P100 titre remained stable on raw 
salmon fillet samples for 4-7 days at 4 °C, while it decreased during the first 4 days of the  
10-day storage period, at 4 °C and 10 °C, of treated catfish samples. Thus, the data provided 
were not adequate to draw firm conclusions on persistence or activity of P100 during the 10-day 
storage of treated fish samples. 
No evidence was provided to demonstrate the impact of treating raw fish on L. monocytogenes 
contamination levels in the finished product. Overall, the evidence provided is not adequate to 
evaluate potential human listeriosis risk reduction by treating raw fish with Listex™ P100. 
Although the experimental evidence available is very limited, it is considered unlikely that the 
proposed use of Listex
TM
 P100 might result in the emergence of reduced susceptibility to 
biocides and/or resistance to key therapeutic antimicrobials. Additionally, testing should 
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monitor the potential for selection and dominance of L. monocytogenes strains naturally-
resistant to P100. 
No information was provided on the survival of P100 in processing wastewater or the 
environment in order to address potential risks related to the release of the processing plant 
effluents, linked to the use of the substance, into the environment. 
Considering the limitations of the proof of concept investigations evaluated by the Panel, it is 
recommended that pilot and industrial scale studies should address parameters such as types and 
size of fish, stage of processing for application of Listex
TM
 P100, multiple and more appropriate 
strains used for inoculation, contamination levels comparable to those naturally present, fish 
sample size and repetitions. Verification is needed that treatment of raw fish with Listex
TM
 P100 
will have an impact on L. monocytogenes contamination levels in the final fish product. The 
persistence or activity of P100 as well as potential changes in L. monocytogenes counts should 
be further evaluated during storage of treated fish samples. The continuous effectiveness of 
Listex
TM
 P100 against L. monocytogenes and the potential for selection and dominance of 
strains naturally resistant to P100 should be monitored. This additional knowledge should be 
provided in order to understand the influence of variables associated with practical applications, 
and, thus, allow commercial operators to select conditions of use that are validated and verified 
according to HACCP principles. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The EU food hygiene legislation is aimed at protecting consumers against potential risks to health and 
maintaining a high level of consumer protection at all stages of the food chain. This objective must be 
achieved by applying the appropriate measures, including good hygiene practices and hazard control 
measures at each step of the food chain. 
According to EU scientific advice
5
, decontamination practices can constitute a useful tool in further 
reducing the number of pathogenic microorganisms but the use of substances intended to remove 
microbial surface contamination should only be permitted if a fully integrated control programme is 
applied throughout the entire food chain. Those substances shall be assessed thoroughly before their 
use is authorised. 
Article 3 (2) of Regulation (EC) No 853/2004 provides a legal basis to approve, and therefore 
authorise, the use of substances other than potable water to remove surface contamination from 
products of animal origin. 
In addition to the safety of the substance, a matter of concern is also the potential emergence of 
reduced susceptibility to biocides and/or the resistance to therapeutic antimicrobials and the impact of 
the substance or its by-products on the environment. 
Therefore, before taking any risk management decision on their approval, a risk analysis should be 
carried out taking into account the results of a risk assessment based on the available scientific 
evidence and undertaken in an independent, objective and transparent manner, other legitimate factors, 
and the precautionary principle. 
EFSA GUIDANCE AS PROVIDED BY THE EUROPEAN COMMISSION 
On 14 April 2010, the European Food Safety Authority (EFSA) issued a revision of a guidance 
document
6
 on the submission of data for the evaluation of the safety and efficacy of substances for the 
removal of microbial surface contamination of foods of animal origin intended for human 
consumption. 
APPLICATION FOR APPROVAL AS PROVIDED BY THE EUROPEAN COMMISSION 
On 15 July 2011, the Commission received an application dossier from Micreos BV (the Netherlands) 
for the approval of Listex
TM
 P100 to remove Listeria monocytogenes surface contamination of raw 
fish. The dossier is enclosed to this request. 
TERMS OF REFERENCE AS PROVIDED BY EUROPEAN COMMISSION 
EFSA is requested to evaluate the safety and efficacy of Listex
TM
 P100 to remove Listeria 
monocytogenes surface contamination of raw fish, considering: 
1. the toxicological safety of the substance; 
2. the efficacy, i.e. does the use of the substance significantly reduce the level of contamination 
of Listeria monocytogenes; 
3. the potential emergence of reduced susceptibility to biocides and/or resistance to therapeutic 
antimicrobials linked to the use of the substance; and 
                                                     
5  SCVPH (Scientific Committee On Veterinary Measures Relating To Public Health), 1998. Report on the benefits and 
limitations of antimicrobial treatments for poultry carcasses, 30 October 1998. SCVPH (2003) Opinion on the evaluation of 
antimicrobial treatments for poultry carcasses (http://ec.europa.eu/food/fs/sc/scv/out14_en.pdf ).  
6  EFSA Journal 2010;8(4):1544. 
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4. the risk related to the release of the processing plant effluents, linked to the use of the 
substance, into the environment. 
Clarification of the terms of reference: 
Following discussion with the Commission services, it was clarified that the following should also be 
considered in the Scientific Opinion: 
1. treatment of only raw fish as the initial material for the production of a variety of products, 
and 
2. persistence of bacteriophages (i.e. continual functioning) in the food. 
APPROACH TAKEN TO ANSWER THE TERMS OF REFERENCE 
After having received this request from the European Commission, the European Food Safety 
Authority (EFSA) assigned the mandate to the Panel on Biological Hazards (BIOHAZ Panel) for 
assessment. The terminology and procedure used by the Panel in this assessment conform with the 
“Guidelines on the submission of data for the evaluation of the safety and efficacy of substances for 
the removal of microbial surface contamination of foods of animal origin intended for human 
consumption” prepared by EFSA (EFSA Panel on Biological Hazards (BIOHAZ), 2010). 
The BIOHAZ Panel adopted all chapters and the respective conclusions of this Opinion on 8 March 
2012. 
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ASSESSMENT 
1. Introduction 
As indicated in the application dossier, the purpose of the proposed treatment is “to eradicate or 
decrease Listeria monocytogenes present on raw fish”. The formulated product has the trade name 
Listex
TM
 P100 and contains bacteriophage P100 at a concentration of 2×10
11
 plaque-forming units 
(pfu) per ml. Approval was sought for spraying or dipping treatments of raw fish using up to 1×10
9
 
pfu of P100 per gram of product. As stated in the application dossier, the concentration to be used 
depends on the log unit reduction desired as well as other factors. 
The aim of the present Opinion is to assess the safety and efficacy of Listex
TM
 P100 to reduce 
L. monocytogenes surface contamination on raw fish considering (1) the toxicological safety of the 
substance, (2) the efficacy, i.e. does the use of the substance significantly reduce the level of 
contamination of L. monocytogenes, (3) the potential emergence of reduced susceptibility to biocides 
and/or resistance to therapeutic antimicrobials linked to the use of the substance, and (4) the risk 
related to the release of the processing plant effluents, linked to the use of the substance, into the 
environment. Each of these assessments is described subsequently. 
2. Product characteristics and conditions of application 
According to the application dossier, Listex™ P100 is a water formulated product that contains 
bacteriophage P100 at a concentration of 2×10
11
 pfu/ml; the molecular weight of one particle of P100 
is approximately 1.2×10
8
 Dalton; and its size is approximately 300 nm. According to Klumpp et al. 
(2008) the size of bacteriophage P100 is, head diameter 89.55 nm, tail length 198.24 nm, tail diameter 
19.0 nm. 
Production of Listex™ P100 is based on a fermentation process using non-pathogenic Listeria innocua 
(Buchrieser et al., 2003) followed by several filtration steps with the objective of removing the 
propagation bacteria and cell debris. To ensure sterility, the final product is evaluated by testing for 
presence of bacteria, yeasts and moulds. The shelf life of Listex™ P100 is considered to be six 
months. 
The application dossier states that Listex™ P100 is not chemically reactive under the conditions of the 
intended use. Bacteriophages consist of a DNA core that is surrounded by a protein shell. Therefore, 
their breakdown products consist of amino acids and nucleic acids, which, as stated by the applicant, 
are already present in abundance in foods of animal origin. 
As indicated in the application dossier, use conditions selected for Listex
TM
 P100 to be effective may 
vary within the following limits, which, as noted by the BIOHAZ Panel, are within those of 
L. monocytogenes growth: 
 temperature: optimum 30 °C, range 1 to 35 °C; 
 pH: optimum 7.7; range 5.5-9.5; 
 water activity: minimum 0.92, optimum 0.99; and 
 Sodium Chloride (NaCl): high tolerance up to saturated solutions. 
 
According to the application dossier, and as further clarified by the applicant, the optimal use of 
Listex
TM
 P100 is dependent upon the specific circumstances of any given situation as in practice most 
fish processing units operate with different raw materials, processing steps, processing conditions, and 
processing times. Specifically, the applicant provided the following clarification: These “activity 
parameters are broad, and meant only to ensure that ListexTM P100 is used under circumstances where 
the product will function properly. In practice, most fish processing units operate with different raw 
materials, processing steps, processing conditions and processing times. The optimal application 
process is therefore dependent upon the specific circumstances of each situation. For raw fish fillets, 
for example, the best time to treat is just after filleting, but with the skin still on”. The applicant also 
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states that “in all cases the intended time-point of treatment is as early in the process as feasible, when 
and where the L. monocytogenes are most susceptible to bacteriophages, and to ensure that 
contaminations are not spread throughout the processing environment and thus become the source of 
recontamination at a later point in time.” 
The use of Listex
TM
 P100 is recommended by the applicant to be either by spraying or dipping in a 
manner that distributes bacteriophages evenly over the treated surface. A manufacturer might normally 
use a dipping process applied for 1 minute. Once Listex™ P100 is applied in the right dose to the 
surface of the product, a time interval of approximately 30 minutes is needed for the bacteriophages to 
find and kill Listeria host cells. 
According to the application dossier, the concentration that is used by the fish processor depends on 
the log units of pathogen reduction desired. In general, the amount of bacteriophage applied should be 
adequate and the exposure time long enough for contact with bacterial cells to occur through diffusion, 
as bacteriophages are non-motile. Overall the concentration used does not exceed 1×10
9
 pfu/g. Since 
Listex
TM
 P100 is applied by spraying or dipping, the activity, survival and inactivation parameters of 
the Listex
TM
 P100 solution should be considered. 
The concentration of bacteriophages required to achieve the desired pathogen reduction varies with 
different foods as the bacteriophages also interact with the food matrix decreasing the amount of and 
the time in which this occurs to varying degrees. An approximate 2-log unit reduction of 
L. monocytogenes on fish filets can typically be achieved with 2×10
7
 bacteriophage per square 
centimetre as long as contact time exceeds 30 minutes. 
There is no step for the neutralization, removal or recycling of Listex™ P100 because, according to 
the application dossier, “there is no: (i) health risk relating to the presence of „residues‟ (toxicological 
safety); and (ii) technological function in the end product.” According to the application dossier, 
“removal of bacteriophages is not necessary because bacteriophages are only active for a limited 
amount of time, their breakdown products are the same as substances already present in food, and lytic 
bacteriophages are not regarded as a health hazard for humans”. 
The treated raw fish are mainly destined for use in the production of cold-smoked and cured fish 
products such as gravlax and cured herring. Also raw fish that will ultimately be cooked before 
consumption is to be considered, for reasons of preventing cross-contamination or product abuse 
downstream of the primary processing steps. 
The applicant further states in the application dossier, that Listex
TM
 P100 should be used as an 
additional risk-reduction measure. There is no standard guarantee that a specific reduction level can be 
achieved through a standard application, and use of the product does not change the manufacturer‟s 
obligations to test end-product safety for product release and certainly not for a lack of proper hygiene. 
It is further stated that regular or intensified testing for L. monocytogenes pre- and after-treatment 
should confirm the results of the Listex
TM
 P100 application. 
3. Public health concerns associated with listeriosis and seafood 
The BIOHAZ Panel has summarized knowledge on the pathogen and the infection through 
consumption of contaminated seafood (presented in Appendix A). 
4. Biology of bacteriophages and use as control agents in food production 
The BIOHAZ Panel, based on the previous EFSA Scientific Opinion on “The use and mode of action 
of bacteriophages in food production” (EFSA, 2009), has also summarized material related to the 
biology and use of bacteriophages as antibacterial agents (Appendix B). Related material was also 
extracted from the application dossier. The specific characteristics of P100 are described in other 
sections. 
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5. Methods of analysis used by the applicant 
According to the application dossier, the analytical methods to detect P100 are a polymerase chain 
reaction (PCR) and a plaque assay. The latter is the standard method to detect and quantify 
bacteriophages. In short, it involves preparation of different dilutions of bacteriophage stock and 
inoculation on susceptible (Listeria spp.) lawns. After incubation, plaques formed by individual 
bacteriophages are counted allowing calculation of their concentration per ml. 
The method used for the detection and enumeration of L. monocytogenes and other Listeria spp., as 
included in Annex 9 of the application dossier, is the UK Health Protection Agency (HPA) Standard 
Method (HPA, 2009). 
6. The toxicological safety of the substance to humans 
6.1. Evaluation 
Three types of parameters were taken into account in evaluating the safety/toxicity of Listex
TM
 P100 
application for Listeria decontamination of raw fish: the potential for temperate bacteriophage 
presence in the L. innocua propagation strain; the bacteriophage P100 itself; the ingredients and mode 
of fabrication of the preparation to be applied and their possible effects on consumers of fish. 
6.1.1. Potential presence of temperate bacteriophages in the ListexTM P100 preparation 
The potential for presence of temperate bacteriophages in the L. innocua propagating strain and their 
transfer in the Listex P100 preparation was not addressed in the application dossier. Also, there is no 
sufficient knowledge of the P100 preparation process to comment meaningfully on the possibility of 
temperate phage 'carry-over'. However, if such an event had occurred, then the two types of 
bacteriophages (i.e. lytic and temperate) should have been phenotypically evident on plates used for 
calculation of concentration. 
Although potentially an issue in certain circumstances, „carry-over‟ of virulence genes by temperate 
bacteriophages should not be of concern in the production process of Listex
TM
 P100 because the 
bacteriophage propagating organism (L. innocua) is not pathogenic and is lacking the virulence gene 
cluster (vgc) of L. monocytogenes (Chakraborty et al., 2000). This implies that even if the L. innocua 
genome contained resident prophages, they would not carry any virulence determinants. In addition, 
temperate bacteriophages usually have narrow host ranges. Thus, even if a L. innocua temperate phage 
contaminated the Listex
TM
 P100 preparations it should not be infective to L. monocytogenes. 
Furthermore, as stated in the application dossier, a routine procedure to check bacteriophage P100 
purity is gel electrophoresis of its DNA. If other bacteriophages were present in sufficient 
concentration, their DNA should be detected by this method. 
6.1.2. The bacteriophage P100 
Bacteriophage P100 was isolated from sewage of a dairy plant on the basis of its ability to lyse 
L. monocytogenes. It belongs to the family Myoviridae, composed of bacteriophages that present 
contractile tails to inject their genomic double stranded DNA molecule into the bacterial hosts. In the 
131 kbp genome of P100, 174 open reading frames encoding for proteins, plus 18 tRNA determinants 
have been mapped (Gen Bank reference: DQ004855) (Carlton et al., 2005). Functions could only be 
ascribed to 25 of the putative proteins, while most of them present diverse degrees of homology to 
those of other bacteriophages such as K, A511, LP65 and SPO1, which infect strains of 
Staphylococcus, Listeria, Lactobacillus and Bacillus, respectively. In addition to this, all of them share 
their morphology, infect low G+C Gram-positive bacteria, are strictly virulent, affect wide spectra of 
susceptible bacterial strains, and, in the cases where this characteristic is known, have terminally 
redundant, non-permuted genomes, all of which justified their inclusion into the SPO1-like group of 
bacteriophages and the proposed subfamily Spounavirinae (Klumpp et al., 2008; Klumpp et al., 2010). 
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Most of these characteristics (including those outlined in section c of Appendix B) are relevant to the 
safe use of bacteriophage P100 for control of Listeria fish-contamination (EFSA Panel on Biological 
Hazards (BIOHAZ), 2009), as follows: 
 exclusively virulent: this eliminates the possibility of generating lysogenic hosts that, by 
definition, would be immune to superinfection by the same virus and that might acquire new, 
bacteriophage encoded, properties (lysogenic conversion); 
 one unit genome packaging: the strict recognition requirement of the DNA sequence termini 
by the bacteriophage terminase will preclude the formation of transducing bacteriophages and 
thus avoid bacterial DNA transfer into their capsids; and 
 broad host range restricted to Listeria: Carlton et al. (2005) indicated that over 95 % of 
approximately 250 different Listeria isolates tested including diverse serovars of 
L. monocytogenes tested were susceptible to P100. No other bacterial genera are affected, thus 
ensuring containment of the treatment (Carlton et al., 2005). In another study (OFIMER, 
2011) using an in vitro test, 78 % of the 42 L. monocytogenes strains isolated from smoked 
salmon and smoked trout, were sensitive to Listex
TM
 P100 tested, while 12 % were classified 
as intermediary, and 10 % as resistant. 
6.1.3. The decontaminating formulation 
This part is based on the information contained in a technical report provided by the applicant. 
As indicated, P100 is propagated on a strain of non-pathogenic L. innocua. The growth medium for 
the host is composed of non-animal ingredients. The applicant provided specifications for the 
ingredients and demonstrated that toxicological relevant impurities were not present. Medium 
sterilization is by filtration, thus avoiding the possible generation of toxic compounds driven by high 
temperature. 
Downstream processing is essentially performed by successive filtrations to separate bacteriophages 
from unlysed bacteria and other debris, for bacteriophage concentration, and for purification of the 
suspensions; the final bacteriophage concentration is adjusted with water and the product is stored at 
4 °C. Adequate controls are performed for microbial contamination and potency of the preparation 
(through titration of viable virions). Finally, the applicant states in the dossier that a HACCP plan and 
Good Laboratory Practices (GLP) are in operation during production. 
6.1.4. The potential effect of bacteriophage P100 on consumer’s health  
As is indicated in Appendix B, bacteriophages are part of the indigenous microbiota of eukaryotic 
organisms, including humans. Bacteriophages are routinely consumed in fermented foods. 
Upon consumption, the bacteriophages numbers should be reduced substantially because they are 
subjected to severely deleterious conditions, such as the stomach acidity and the attack by digestive 
proteinases including pepsin and trypsin (the capsid is made out of protein). Furthermore, commercial 
use of phage-based preparations has been granted by the US Food and Drug Administration (US FDA) 
for use on ready-to-eat (RTE) foods, which are considered to be GRAS (Generally Regarded As Safe) 
in the USA. Among them is Listex P100 itself and a range of other preparations such as LMP-102, 
also active against L. monocytogenes, Agriphage, used against tomato and pepper spot and even anti-
Escherichia coli and anti-Salmonella washes for live animals prior to slaughter (Coffey et al., 2010; 
Hagens and Offerhaus, 2008). 
Furthermore, the raw fish treated with P100 should in most cases be processed before consumption. 
Processing, such as cooking, should inactivate the bacteriophage because bacteriophages do not 
survive when exposed for a few minutes to temperatures above 70 °C. Additional processes such as 
marinating, curing and freezing may also be deleterious to bacteriophages. It needs to be noted that in 
some cases fish may also be consumed raw (e.g. sushi). 
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6.1.5. Possible reserves 
 Bacteriophage P100 does not harbour any gene whose product is homologous to bacterial 
toxins or other virulence factors; this should serve as proof of safe application. It should be 
noted, however, a majority of the open reading frames of P100 encode proteins with no 
matches in relevant databases. This may indicate the possibility of a toxinogenic potential. In 
fact, protein gp71 of the bacteriophage appears to present in its C-terminal end short stretches 
which are similar to the allergenic protein γ-gliadin (Carlton et al., 2005). A consultation with 
the allergy expert of the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA 
Panel) led to the conclusion that “gp71 is unlikely to trigger an allergic reaction in wheat 
sensitive individuals even if it were equal in allergenic potency to the wheat protein gamma-
gliadin, given the small amounts of phage protein that is predicted to be present on the fish 
even when the „worst case scenario‟ is contemplated”. In addition, as described by Carlton et 
al. (2005), an oral toxicity study has been performed on ten rats of about 8 weeks of age. The 
authors claim that feeding these rats with 5×10
11
 bacteriophages/day for five consecutive days 
did not reveal any alterations in their survival, body weight, behaviour, or appearance and the 
necropsy results were normal. This study was performed according to OECD GLP principles. 
 It is not clear whether the ListexTM P100 phage-manufacturing procedures will eliminate cell 
debris such as host cell wall fragments. These, and especially the teichoic acid/lipoteichoic 
acid fractions, might interact with toll receptors on the surface of the myeloid cells and act as 
immune adjuvants, as might do the P100-lysed contaminating Listeria. According to the NDA 
Panel expert, this should be no cause for concern. Reasons for this include the expected very 
low degree of contamination on fish and its treatment before any substantial bacterial growth. 
Additional considerations indicated by the NDA Panel expert are the large amounts of 
bacterial debris present in some foods (e.g. some fermented foods), and the vast number of 




 P100 preparation should not pose a risk to human health because: bacteriophage P100 
fulfills the safety requirements included in the QPS Opinion (EFSA Panel on Biological Hazards 
(BIOHAZ), 2009); the remnants of the digested bacteriophage are of no health concern; the chemicals 
and other parameters used in its manufacture do not include any obvious components or steps that 
might compromise safe use. Two possible reserves considered should not be relevant for the uses and 
conditions sought in the application. They are the lack of putative function ascribable to most of its 
proteins and the lack of a specific control for presence of Listeria cell wall fragments in the 
preparation. 
7. The efficacy, i.e. does the use of the substance significantly reduce the level of 
contamination of pathogenic microorganisms 
7.1. Introduction 
In order to assist in assessing the efficacy of a decontaminating agent, EFSA issued in 2010 a revised 
guidance document (EFSA Panel on Biological Hazards (BIOHAZ), 2010) which points out the major 
components and data that an application dossier should contain in order to demonstrate that the 
substance intended to be used for the reduction of microbial surface contamination of foods of animal 
origin is efficacious. These guidelines have been used in this assessment of Listex
TM
 P100 for use in 
the decontamination of raw fish relative to L. monocytogenes. 
According to the EFSA guidance document, the use of substance(s) as decontaminating treatments 
will be regarded efficacious when any reduction of the prevalence and/or numbers of pathogenic target 
microorganisms is statistically significant as compared to the control (e.g. water) and, at the same 
time, this reduction has a positive impact on reduction of human illness cases. Risk assessment studies 
on other microbial species (EFSA Panel on Biological Hazards (BIOHAZ), 2011a, 2011b) have shown 
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that even 0.5 log10 unit microbial reductions may reduce consumer risks to a significant extent. In 
addition, there is a linear correlation between reductions in prevalence and reductions of consumer 
risks. Efficacy depends on a range of factors such as concentration of the decontaminating agent, the 
microbial pathogen and its load of the surface, contact time, temperature, mode of application, and 
other conditions of application. 
7.2. Selection of studies for evaluation of efficacy 
The application dossier summarizes the data from five peer-reviewed published papers and one project 
report examining the efficacy of Listex
TM
 P100 on various food products. The applicant seeks 
approval for treatments of raw fish using up to 10
9
 pfu/g of food product as early in the process as 
feasible and applied either by spraying or dipping, with broad limits of conditions (temperature, pH, 
water activity and NaCl level) as specified above. 
The body of evidence from the studies submitted in the application dossier was evaluated by the EFSA 
BIOHAZ Panel, taking into account whether the studies were done in the laboratory, a pilot plant or a 
processing plant, and whether they used inoculated or naturally contaminated fish. Table 1 presents 
how combinations of industrial-, pilot- or laboratory-scale study settings and evaluation of natural or 
inoculated contamination were used to classify the strength of evidence of the data in each study. 
These criteria were originally presented in the FAO/WHO report on Benefits and Risks of the Use of 
Chlorine-containing Disinfectants in Food Production and Food Processing (FAO/WHO, 2008), and 
were adapted from a previous EFSA Opinion (EFSA Panel on Biological Hazards (BIOHAZ), 2011b). 
Table 1:  Relative strength of the contribution of study data to the general body of evidence, based 
on study type (based on EFSA Panel on Biological Hazards (BIOHAZ) (2011b)) 
Study type Natural contamination Inoculated studies 













a Experiments using industrial equipment in non-industrial settings. 
b If the pilot process is representative of the industrial process; otherwise, evidence makes a „medium‟ contribution to the 
body of evidence. 
c Data would not be sufficient to inform a quantitative microbial risk assessment or to allow definitive conclusions on risk 
reduction. 
d Data are indicative of a disinfectant effect that may be reproducible in practice, but individually do not allow definitive 
conclusions on risk reduction. 
 
Of the six papers submitted for consideration, four were excluded from the evaluation because the 
studies described were outside the scope for which the applicant is seeking approval. More 
specifically, these four papers were excluded because food products other than raw fish were 
examined (Table 2). 
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Table 2:  The six papers submitted by the applicant and the reasons for inclusion/exclusion of 










Microorganisms Product treated Strength 
of 
evidence 





YES  Lab Inoculated L. monocytogenes Raw salmon 
filet 
Low 
OFIMER (2011) NO Raw fish not 
useda 
     
Guenther et al. (2009) NO Raw fish not 
usedb 
     
Holck and Berg 
(2009) 
NO Raw fish not 
usedc 
     
Carlton et al. (2005) NO Raw fish not 
usedd 
     
a Smoked salmon used. 
b Hot dogs, sliced turkey meat, smoked salmon, seafood (cooked and chilled cocktail of shrimp, mussels and calamari), 
sliced cabbage, and lettuce leaves used. 
c Sliced cooked ham used. 
d Surface-ripened red-smear soft cheese used. 
 
The assessment of the efficacy of Listex
TM
 P100 to remove L. monocytogenes surface contamination 
of raw fish was therefore based on two of the six papers included in the application dossier. The 
papers included in the evaluation described studies with low strength of evidence and using inoculated 
fresh channel catfish (Soni et al., 2010) and raw salmon (Soni and Nannapaneni, 2010) fillet samples. 
7.3. Evaluation of studies on efficacy 
The influence of bacteriophage dose, bacteriophage contact time, and storage temperature on the 
listericidal activity of P100 in reducing the inoculated L. monocytogenes loads on the surface of fresh 
channel catfish fillets is described in Soni et al. (2010). More specifically, according to Soni et al. 
(2010), the P100 stock solution of approximately 10
11
 pfu/ml in buffered saline, as determined by 
plaque formation assay, was serially diluted in physiological saline to prepare the desired application 
concentrations. Duplicate 5 g samples of fresh catfish (approximately 2 cm
2
 top surface area) were 
inoculated with 50 µl of a two-strain mixture (strains, EGD (BUG 600; serotype 1/2a) and strain Scott 
A (serotype 4b)) of L. monocytogenes suspension to yield an inoculation level of approximately 4.3 
log10 cfu/g. The inoculum was uniformly spread on the white flesh fillet surface side by random 
spotting at five points of 10 µl each on the flesh side. The inoculum was air-dried for 15 min before 
treatment. In addition, large fillets (approximately 180–200 g) were also inoculated with 2 ml of the 
serially diluted two-strain mixture of L. monocytogenes and air-dried for 15 min to yield 
L. monocytogenes inoculation levels of about 4 log10 cfu/g. After inoculation, the 5 g catfish fillet 







to yield final application doses of 2×10
7
 pfu/g (7.3 log10 pfu/g), 2×10
5
 pfu/g (5.3 log10 pfu/g), or 2×10
3
 
pfu/g (3.3 log10 pfu/g), respectively. For the no bacteriophage control, the fillet pieces were surface 
treated with 100 µl saline. Duplicate fillet samples in a weighing dish were sealed in Ziploc bags 
(16.5×14.9 cm) and incubated at 4 °C, 10 °C, or 22 °C. After incubation for 15 min, 30 min, 1 h, 2 h, 1 
day, 4 days, 7 days, or 10 days, the fillet samples were subjected to L. monocytogenes enumeration. 
All experiments were repeated three times with two replications. Each large fillet was sprayed with 7.5 
ml of Listex
TM
 P100 suspension of 10
9 
pfu/ml evenly on the entire white-flesh side using a hand-held 
spray bottle (2 oz mini fingertip sprayer). Untreated control fillets were sprayed with the same amount 
of saline. After 30 min or 2 h contact time with Listex
TM
 P100 at 22 °C, fillets were enumerated for 
L. monocytogenes. Experiments were repeated twice. 
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According to the results, the L. monocytogenes reduction by P100 on fresh catfish fillet samples (5 g) 
was influenced by bacteriophage contact time and bacteriophage dose regardless of higher or lower 
temperature regimes tested. The reduction in L. monocytogenes loads (p < 0.05) with the P100 dose of 
7.3 log10 pfu/g was 1.4–2.0 log10 cfu/g at 4 °C, 1.7–2.1 log10 cfu/g at 10 °C, and 1.6–2.3 log10 cfu/g at 




pfu/g had no or minor effect on 
L. monocytogenes. The bacteriophage contact time of 30 min was adequate to yield 1.3-1.6 log10 cfu/g 
reduction in L. monocytogenes, whereas 15 min contact time with bacteriophage yielded less than 1.0 
log10 cfu/g reduction in L. monocytogenes loads on catfish fillets. Maximum reductions at 22 °C were 
achieved after 30 min of exposure, while no further reductions were detected after 30 min and up to 
120 min. Reductions in large catfish fillets treated with 7.3 log10 pfu/g for 30 and 120 min at 22 °C 
were 1.7-2.3 log10 cfu/g. 
Surviving L. monocytogenes counts demonstrated an upward trend over the 10-day shelf life at 4 °C or 
10 °C, while P100 titres on the catfish fillet samples, from the initial level of 7.3 log10 pfu/g, decreased 
to 5.5 and 5.2 log10 pfu/g during the 10-day shelf life at 4 °C and 10 °C, respectively. These results 
indicate a maximum loss of approximately 1.8–2.1 log10 pfu/g in P100 concentrations during 10 days 
of storage for fresh catfish fillets. It should be noted that reductions were mostly noticeable during the 
first 4 days of storage. These results would indicate that after addition to the food, bacteriophages 
become inactive, as indicated in the application dossier. According to the submitted dossier, active 
bacteriophage numbers decline from the moment of application due to various factors like adsorption 
of bacteriophages to particles, proteolytic degradation of the bacteriophage particle by chemicals and 
enzymes, temperature, salts and light (Garza and Suttle, 1998; Hurst et al., 1980; Suttle and Chen, 
1992); eventually, bacteriophages fall apart into amino acids and nucleic acids. 
The antilisterial activity of Listex
TM
 P100 on the surface of raw salmon fillet tissue against 
L. monocytogenes serovars 1/2a and 4b was examined by Soni and Nannapaneni (2010). Fresh, whole 
raw salmon fillet tissue samples of approximately 2-cm
2
 blocks (10 g) were prepared with the flesh 
side facing up. For evaluation of the effect of different P100 concentrations on L. monocytogenes 
reduction each raw salmon sample was inoculated with 50 µl of a serially diluted, two-strain (serotype 
1/2a and 4b) mixture to yield an inoculation level of approximately 4 log10 cfu/g. Samples were 






















respectively. For the untreated control, each sample received 100 µl of saline solution. The duplicate 
samples per treatment were placed in a polystyrene dish, sealed immediately in a Ziploc bag for 
incubation at 4 °C for 2 h, and then enumerated for L. monocytogenes. To study the effect of P100 
against low and high L. monocytogenes inoculum levels, serial dilutions of the pathogen cell 
suspension were spot inoculated at 50 µl to yield 2, 3, or 4 log10 cfu/g on the flesh side of the 10-g raw 
salmon tissue sample. These tissue samples were then surface treated with P100 by adding 100 µl of 
bacteriophage suspension to the flesh side, for a bacteriophage application dose of 10
8
 pfu/g per 10 g 
of tissue sample. Each treatment, which consisted of duplicate tissue samples in a polystyrene dish, 
was immediately packed in a Ziploc bag for incubation at 4 °C or 22 °C, and then enumerated for 
L. monocytogenes after 30 min and 2 h. The effect of P100 on L. monocytogenes growth during the 
shelf life of raw salmon fillet tissue was examined by inoculating 10-g samples of raw salmon fillet 
tissue with approximately 2 log10 cfu/g of L. monocytogenes serotype mixture (1/2a and 4b) and 
treating the samples with P100 by applying 100-µl of bacteriophage suspension to the flesh side to 
give a bacteriophage dose of 10
8
 pfu/g. After treatment, the polystyrene dish containing duplicate 
tissue samples was immediately packed in a Ziploc bag for storage at 4 °C, and analyzed for 
L. monocytogenes levels at 0, 1, 4, 7, and 10 days. 
The results (Soni and Nannapaneni, 2010) indicated that on raw salmon fillet tissue, a bacteriophage 
concentration of 10
8
 pfu/g was required to yield 1.8-, 2.5-, and 3.5-log10 cfu/g reductions of 
L. monocytogenes from its initial loads of 2, 3, and 4 log10 cfu/g at 4 or 22 °C. From the initial load of 
1.6 log10 cfu/g, over the 10 days of storage at 4 °C, L. monocytogenes growth was limited on the 
treated raw salmon fillet tissue to as low as 0.3 log10 cfu/g versus normal growth of 2.6 log10 cfu/g in 
the absence of bacteriophage. Bacteriophage P100 remained stable on the raw salmon fillet tissue over 
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a 10-day storage period; with only a marginal loss of 0.6 log pfu/g from an initial bacteriophage 
treatment of 8 log10 pfu/g during the last days of storage. This is in contrast to the results of Soni et al. 
(2010) with catfish fillets summarized above. 
In general, as indicated in the application dossier, the two papers of Soni et al. (2010) and Soni and 
Nannapaneni (2010), tested P100 efficacy on L. monocytogenes on both salmon and catfish fillets. In 
catfish, an average reduction of 1.5 log10 cfu/g was achieved within 30 minutes after application. In 
whole catfish a reduction between 1.4 and 2.0 log10 cfu/g (10 °C) was achieved with a bacteriophage 
concentration of 2×10
7
 pfu/g. On raw salmon fillet tissue treatment with 10
7
 pfu/g resulted in a 2 log10 
cfu/g reduction and 10
8
 pfu/g resulted in a 3.5 log10 cfu/g reduction of L. monocytogenes. Listeria 
reductions were proportional with the applied bacteriophage concentration. It was demonstrated that 
P100 was able to reduce L. monocytogenes on raw fish fillets as a function of bacteriophage dose, 
inoculum level, and contact time, while temperature had a minor effect. 
7.4. Considerations of studies on efficacy 
According to the EFSA guidance (EFSA Panel on Biological Hazards (BIOHAZ), 2010), the 
processing conditions used to evaluate the efficacy must be comparable with those for which the 
formulated product is intended and tests must be made with inoculated target microorganisms, taking 
into account strain diversity. This can be achieved using different strains or cocktails of strains and 
strains isolated from the surface of the foods to be treated. The studies included in the evaluation 
examined activity of the formulated product against only two strains of L. monocytogenes. Further, 
strain Scott A is not considered as being representative of recent foodborne outbreaks or of average 
growth, resistance and survival characteristics for L. monocytogenes strains (Barbosa et al., 1994; 
Lianou et al., 2006), produces aberrant morphological colonies on selective media (Loessner et al., 
1988), and spontaneously produces cell wall deficient L-forms (Dell'Era et al., 2009). No 
L. monocytogenes strains of fish origin were included in the studies evaluated. 
Soni et al. (2010) concluded that “since there is high diversity of L. monocytogenes isolates that may 
occur in catfish fillets and in processing plants, further work is needed to determine the ability of P100 
in eliminating the diverse set of isolates of L. monocytogenes occurring in these conditions.” In 
addition, Soni and Nannapaneni (2010) indicated that “experiments with whole fillets (to mimic the 
commercial fillet processing operation) are needed to test the efficacy of P100 against the wide range 
of L. monocytogenes isolates that frequently originate in salmon fillet processing facilities.” 
The studies, that were considered and evaluated in this Opinion (Soni and Nannapaneni, 2010; Soni et 
al., 2010), used bacteriophage concentrations of 10
8
 pfu/g on raw salmon fillet tissue inoculated with 
2-4 log10 cfu/g L. monocytogenes and resulted in reductions of 1.8-3.5-log10 cfu/g. Reductions on raw 
catfish fillet tissue treated with 7.3 log10 pfu/g P100 were 1.4-2.3 log10 cfu/g when the inoculated level 




log10 pfu/g had either no or only minor effects. The 
following need to be noted: natural L. monocytogenes contamination is usually present on fish at levels 
lower than those evaluated; natural contamination on fish is not spread evenly or uniformly; the non-
motile bacteriophage particles need to come in contact with bacterial cells for action. Thus, the 
efficacy of the proposed Listex™ P100 treatment may need to be evaluated on fish containing lower 
levels of L. monocytogenes contamination in order to determine efficacy under conditions more 
representative to real life. This is also important because L. monocytogenes is a psychrotroph and 
survivors may grow during refrigerated storage of fish. 
As discussed in Appendix C, main potential sources of fish product contamination include the raw 
material and the processing environment. However, the initial origin of processing plant contamination 
remains undetermined (Autio et al., 1999; Autio et al., 2003). In general, L. monocytogenes 
contamination of the processing environment and final product may be variable among processing 
plants as it may originate from incoming raw materials (e.g. fish, water, ice), other materials (e.g. 
packaging, additives), biofilms on equipment and other surfaces, and to a lesser extent employees in 
the production line. Thus, since L. monocytogenes contamination of processed fish cannot be 
attributed to a single source or processing step, no single decontamination treatment could solve the 
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problem. Further, since contamination can occur at multiple steps, re-contamination of fish post-
decontamination may also occur; this might diminish or negate the anti-listerial contribution of 
previous decontamination treatments. Therefore, any anti-listerial decontamination treatment(s) would 
need to be verified as useful at the production step implemented as well as for its contribution to 
reduction of contamination in the finished product and to reduction of listeriosis associated with 
consumption of fish. Since the length of time that the bacteriophage remains active was not 
sufficiently documented in the studies examined, the overall efficacy of the Listex™ P100 
decontamination could not be assessed throughout the fish processing chain. 
Overall, the impact of treating raw fish with Listex
TM
 P100, as early in processing as possible, on the 
contamination of the final product and its impact on listeriosis reduction needs to be established. 
Processors also would need specific guidance for proper implementation of the treatment. 
7.5. Conclusions 
 Based on the selection criteria, a total of two of the six submitted papers were included in the 
assessment of the efficacy of Listex
TM
 P100 as a decontaminating agent against 
L. monocytogenes on raw fish. 
 The two laboratory studies, selected for evaluation were classified as of „low strength of 
evidence‟. According to the study selection criteria, when a study is classified as of „low 
strength of evidence‟, “data are indicative of a disinfectant effect that may be reproducible in 
practice, but individually do not allow definitive conclusions on risk reduction.” 
 The data presented in the two selected studies indicated that the bacteriophage ListexTM P100 
was listericidal on inoculated fresh catfish and salmon fillet samples under laboratory 
conditions. 
 Listeria reductions achieved increased with applied bacteriophage concentration and were 
affected by pathogen inoculum level and contact time, while temperature (4 °C and 22 °C) had 
a minor effect. 
o On raw salmon fillet tissue, a bacteriophage concentration of 108 pfu/g yielded 1.8-, 2.5-, 
and 3.5-log10 cfu/g reductions of L. monocytogenes from its initial loads of 2, 3, and 4 
log10 cfu/g at 4 °C or 22 °C. 
o On raw catfish fillet tissue, bacteriophage P100, applied at 7.3 log10 pfu/g at 4 °C, reduced 




log10 pfu/g had either no or only minor effects.  
o Bacteriophage contact time of 30 min caused greater than 1 log10 cfu/g reduction in 
L. monocytogenes, while reductions at 15 min contact time were less than 1 log10 cfu/g of 
catfish fillet.  
 The data provided were not adequate to allow conclusions on the fate of the bacteriophage 
P100 and of surviving L. monocytogenes during product storage after treatment. 
o Listeria monocytogenes counts showed an upward trend in treated catfish fillets stored for 
10 days at 4 °C or 10 °C, which was not evident in treated salmon fillets stored for 10 
days at 4 °C. It is unclear whether these counts were due to total prevention of bacterial 
growth or to the balance between growth and death of bacterial cells. 
o The bacteriophage P100 titre remained stable on raw salmon fillet samples for 4-7 days 
and showed slight reductions during days 7-10 at 4 °C. In contrast, P100 titres decreased 
during the first 4 days of the 10-day storage period of treated catfish samples at 4 °C and 
10 °C, and remained stable during days 4-10. 
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 The two studies considered had the following limitations: 
o Experiments were conducted exclusively under laboratory conditions with the objective of 
proof of concept. 
o The results were not validated under pilot plant or industrial conditions. 
o These studies selected for assessment evaluated only two types of fresh fish and 
conditions such as tissue or skin differences or other variables among other types of fresh 
fish based on composition, muscle properties, etc. were not considered. 
o Replication was limited and sizes of samples were mostly small (5 g and 10 g of fresh, 
approximately 2 cm
2
 top surface area, catfish and salmon, respectively), and only a limited 
number of larger samples were treated. Such small samples may not allow evaluation of 
uniformity of application and variability of activity.  
o Although previous studies may have found bacteriophage P100 effective against more 
strains, only a two-strain, two-serotype mixture of L. monocytogenes was tested and no 
strains of fish origin were included in the studies evaluated. This does not allow 
consideration of strain variability in terms of survival ability and growth. 
 Levels and distribution of natural L. monocytogenes contamination on fresh fish may be lower 
and not as uniformly distributed as were those evaluated in the studies examined. Therefore, 
the proposed Listex™ P100 levels may not be adequately efficacious in naturally and 
randomly contaminated fish with lower levels of this psychrotrophic pathogen. 
 No evidence was provided to demonstrate the impact of treating raw fish on L. monocytogenes 
contamination levels of finished product. 
 The continuous effectiveness of ListexTM P100 against L. monocytogenes during repeated use, 
and the potential for selection and dominance of strains naturally resistant to bacteriophage 
P100 were not evaluated. 
 Overall, the documentation and evidence provided is not adequate to allow estimation of 
potential human listeriosis risk reduction by treating raw fish with Listex™ P100. 
8. The potential emergence of reduced susceptibility to biocides and/or resistance to 
therapeutic antimicrobials linked to the use of the substance 
8.1. Evaluation including comments to application 
8.1.1. Treatment of listeriosis 
Because of the relatively few prospective trials on the efficacy of different antibiotic regimens for the 
treatment of invasive listeriosis, the choice of antibiotic for first-line therapy is still debatable 
(Mylonakis et al., 1998). It is generally agreed that the most effective antibiotics are 
ampicillin/amoxicillin or penicillin G in combination with an aminoglycoside, which is classically 
gentamicin (Charpentier and Courvalin, 1999; Hof, 2003). For patients that cannot be treated with 
penicillins, second-choice antimicrobials include trimethoprim in combination with a sulphonamide 
such as sulphamethoxazole (Hof, 2003). Favourable results have also been reported on occasions with 
tetracyclines and erythromycin (Lorber, 1997). Treatment with fluoroquinolones is controversial. 
Favourable in vivo effects with moxifloxacin have been observed in experimental rabbits, but 
conversely the development of listerial meningitis during ciprofloxacin treatment has also been 
reported (Grumbach et al., 1999).  
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8.1.2. Resistance to biocides and therapeutic antimicrobials  
8.1.2.1. Biocides 
There is evidence, which indicates that, the use of biocides, and in particular Quartenary Ammonium 
Compounds (QACs), is linked to the emergence and persistence of strains of L. monocytogenes with 
decreased susceptibility to such compounds. Increased resistance to disinfectants in L. monocytogenes 
within the poultry processing environment was reported by Earnshaw and Lawrence (1998); Lemaître 
et al. (1998) reported a higher proportion of isolates of L. monocytogenes with enhanced resistance to 
biocides in isolates from poultry and food than from humans; and Mereghetti et al. (2000) reported on 
the occurrence of isolates of L. monocytogenes with decreased sensitivity to QACs in isolates from 
food. In contrast, in a comprehensive review of the use of biocides in the food processing industry, 
Holah et al. (2002) reported that there were no differences in susceptibility to biocides in strains of 
L. monocytogenes and E. coli isolated from factory environments in the UK over a three-year period 
when compared to the levels in control laboratory strains of these organisms. 
8.1.2.2. Therapeutic antimicrobials 
Tetracycline resistance is the most frequent resistance trait in clinical isolates. In a study in the UK of 
1 288 clinical isolates made between 1967 and 1990, 33 isolates were found to exhibit resistance to 
this antimicrobial (MacGowan et al., 1990). In a more recent study in France, 1.27 % of isolates 
exhibited resistance to tetracyclines, with resistance to both tetracyclines and fluoroquinolones 
emerging (Morvan et al., 2010). The first strain of L. monocytogenes with multiple resistance to 
therapeutic antimicrobials was reported in 1990. The strain, a clinical isolate originating in France in 
1988, exhibited resistance to chloramphenicol, erythromycin, streptomycin and tetracyclines. 
Resistance was transferable to other strains of L. monocytogenes, and also to enterococci and S. aureus 
(Poyart-Salmeron et al., 1990). Subsequently sporadic isolates of L. monocytogenes with resistance to 
a range of therapeutic antimicrobials from cases of human infection have been increasingly reported 
(for review, see Charpentier and Courvalin (1999)). 
In contrast, resistance to therapeutic antibiotics in L. monocytogenes from retail foods is rare, and was 
only observed in less than 1 % of the isolates of L. monocytogenes in a study of 1 001 Listeria isolates 
from 67 retail food samples (Walsh et al., 2001). In contrast there was a substantially higher incidence 
of resistance to tetracyclines, and penicillin G (>6 %) in isolates of L. innocua, suggesting species 
specificity in the acquisition of resistance within the genus. In a similar study of 202 isolates of 
L. monocytogenes from food and the environment from 1996 to 2006 in France, only four strains 
exhibited resistance, with resistance to erythromycin, tetracyclines and trimethoprim observed 
(Granier et al., 2011).  
Resistance to therapeutic antibiotics can emerge in L. monocytogenes by the acquisition of three types 
of mobile elements – self-transferable plasmids; mobilisable plasmids; and conjugative transposons 
(Charpentier and Courvalin, 1999). Genes conferring resistance to chloramphenicol, macrolides, 
lincosamides and streptogramins have been transferred to Listeria from Enterococcus-Streptococcus 
by plasmid pIP501, and thence between species of Listeria (Perez Diaz et al., 1982). Mobilisation of a 
non-conjugative resistance plasmid of Bacillus subtilis between different species of Listeria by 
plasmid pRYC16, which is widespread in Listeria spp. has been reported (Vicente et al., 1988); and 
transfer of the broad host range conjugative transposon Tn916 mediating resistance to tetracyclines 
from a Streptococcus donor strain to Listeria has also been reported (Vicente et al., 1988).  
To our knowledge there are as yet no reports on the acquisition of resistance genes to therapeutic 
antibiotics by Listeria spp. by bacteriophage-mediated transduction. 
8.1.3. Listeria bacteriophage P100 
Listeria bacteriophage P100 is regarded as a virulent, lytic broad-host range Listeria phage closely 
related to the broad-range Listeria phage A511, and as such is regarded as being not capable of 
transduction (Klumpp et al., 2008). Previous EFSA Opinions (EFSA, 2009; EFSA Panel on Biological 
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Hazards (BIOHAZ), 2009) have given the basis to conclude that P100 is safe because it fulfils the 
requirements that it is a lytic bacteriophage and it is unable to transduce bacterial DNA. These 
conclusions have been confirmed in the application dossier by Professor M.J. Loessner
7
 (Annex 12 of 
application dossier). 
Although experimental data have not been provided, based on the properties of P100 as listed above, it 
is concluded that the use of this bacteriophage for the removal of L. monocytogenes surface 
contamination of raw fish under the conditions specified by the applicant is unlikely to result in the 
potential emergence of reduced susceptibility to biocides and/or resistance to key therapeutic 
antimicrobials. 
8.1.4. Reduced susceptibility of Listeria strains 
The possibility for selection of P100-resistant Listeria variants as a consequence of the use of Listex™ 
P100 needs consideration. In the case of bacteriophages, most of bacteriophage-insensitive mutants 
present altered receptors. The wide host-range of P100 suggests that its receptor may be a common 
trait of the cell envelope and thus might be important for its biological fitness. In that case, 
modification of the receptor would result in poorly-competing strains. 
8.2. Conclusions 
 From the documentation provided, it appears unlikely that the use of ListexTM P100 for the 
removal of L. monocytogenes surface contamination of raw fish, under the conditions 
specified by the applicant, will result in the potential emergence of reduced susceptibility to 
biocides and/or resistance to key therapeutic antimicrobials. Nevertheless this conclusion may 
need verification since the applicant has provided very limited data in support of this 
statement.  




9. The risk related to the release of the processing plant effluents, linked to the use of the 
substance, into the environment 
9.1. Evaluation of risk by the applicant 
The applicant has pointed out that on fresh and processed dairy and meat products more than 10
8
 
viable bacteriophages per gram are often present (Kennedy and Bitton, 1987). Also bacteriophages are 
often consumed in food in high numbers (Hagens and Loessner, 2007, 2010), are normal commensals 
of humans and animals, and are especially abundant in the gastrointestinal tract (Letarov and Kulikov, 
2009). Taking these and other information into account the applicant concludes that the release of 
Listex
TM
 P100 into the environment does not involve any risk. The applicant also states “because 
bacteriophages can only survive and replicate in the presence of their host bacterium, in this case 
Listeria spp., if this host is not present they will disintegrate within a short amount of time due to 
adsorption, UV light and other substances present in water or soil”. In Annex 11 of the application 
dossier five studies are cited (Guenther et al., 2009; Loessner et al., 1996; Loessner et al., 1997; van 
der Mee-Marquet et al., 1997; Zink and Loessner, 1992) following a literature search (OvidSP, 
PubMed, Scopus) by the applicant on „the involvement of the micro-organism in adverse ecological 
effects‟ with respect to P100 and the closely related bacteriophage A511. Based on this literature 
search, the applicant has concluded that “bacteriophage P100 is probably not involved in any adverse 
ecological effects”. 
Nevertheless certain bacteriophages used as indicators of faecal contamination (e.g., Microviridae, 
Siphoviridae and Myoviridae) can persist for up to 90 days in water, and under a range of conditions 
                                                     
7  M. J. Loessner is Professor at the Institute of Food, Nutrition and Health, Swiss Federal Institute of Technology Zurich, 
Zurich, Switzerland. 
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of heat and UV (Lee and Sobsey, 2011). Tests to monitor the survival of P100 in processing 
wastewater and the environment are therefore recommended.  
9.2. Conclusion 
 Scrutiny of the papers cited by the applicant did not reveal any information relating directly to 
the survival of P100 in the environment following its use for L. monocytogenes control, nor 
was any information provided about its ability to survive in wastewater. As far as can be seen 
from the application dossier, there have been no studies undertaken by the applicant to assess 
survival times of P100 at the concentrations proposed for use in processing plant effluents.  
CONCLUSIONS AND RECOMMENDATIONS 
CONCLUSIONS 
TOR 1: Conclusions in relation to the toxicological safety of the substance 
 The ListexTM P100 preparation should not present toxicological problems if used in fish 
decontamination because: 
o The bacteriophage P100 used as active principle is not regarded as harmful to consumers. 
o The ListexTM P100 fabrication parameters do not include any components or steps that 
might compromise safe use of the preparation. 
TOR 2: Conclusions in relation to the efficacy, i.e. does the use of the substance significantly 
reduce the level of contamination of Listeria monocytogenes 
 Although the data of the two low strength of evidence relevant studies considered are 
indicative of a disinfectant effect that may be reproducible in practice, as conducted, the 
studies do not allow definitive conclusions on the efficacy of the product in reducing Listeria 
monocytogenes counts on raw fish.  
 Data presented demonstrated that ListexTM P100 is listericidal (reductions were in the range of 
1.4 to 3.5 log10 cfu/g) on the two inoculated raw fish types (i.e., fresh catfish and salmon fillet 
samples) tested. 
 Among other limitations, the studies evaluated only a two-strain, two-serotype mixture of 
L. monocytogenes (no strains of fish origin were included). 
 The data provided were not adequate to draw firm conclusions on persistence or activity of the 
bacteriophage P100 during storage of treated fish samples. 
 The data provided were not adequate to draw firm conclusions on the fate of surviving 
L. monocytogenes organisms during storage of treated fish samples. 
 Efficacy of the proposed Listex™ P100 treatment against levels of L. monocytogenes usually 
expected to occur naturally on fish was not studied. 
 No evidence was provided to demonstrate the impact of treating raw fish on L. monocytogenes 
contamination levels in the finished product.  
 Overall, the evidence provided is not adequate to allow estimation of potential human 
listeriosis risk reduction by treating raw fish with Listex™ P100. 
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TOR 3: Conclusions in relation to the potential emergence of reduced susceptibility to biocides 
and/or resistance to therapeutic antimicrobials linked to the use of the substance 
 Although experimental evidence on this issue is very limited, the proposed use of ListexTM 
P100 is considered unlikely to result in the emergence of reduced susceptibility to biocides 
and/or resistance to key therapeutic antimicrobials. Nevertheless this conclusion may need 
verification. 




TOR 4: Conclusions in relation to the risk related to the release of the processing plant effluents, 
linked to the use of the substance, into the environment 
 No information was provided on the survival of P100 in processing wastewater or the 
environment. 
RECOMMENDATIONS 
 Considering the limitations of the proof of concept investigations evaluated by the Panel, pilot 
and industrial scale studies should be considered to address parameters such as types and size 
of fish, stage of processing for application of Listex
TM
 P100, multiple and more appropriate 
strains used for inoculation, contamination levels comparable to those naturally present, fish 
sample size and repetitions. 
 Verification is needed that treatment of raw fish with ListexTM P100 will have an impact on 
L. monocytogenes contamination levels in the final fish product. 
 The persistence or activity of P100 as well as potential changes in L. monocytogenes counts 
should be further evaluated during storage of treated fish samples. 
 The continuous effectiveness of ListexTM P100 against L. monocytogenes and the potential for 
selection and dominance of strains naturally-resistant to P100 should be monitored. 
 This additional knowledge should be provided in order to understand the influence of 
variables associated with practical applications, and, thus, allow commercial operators to 
select conditions of use that are validated and verified according to HACCP principles. 
DOCUMENTATION PROVIDED TO EFSA 
1. Letter Ref. Ares(2011)889537 received on 19 August 2011 including the request from the 
Commission and the application dossier from Micreos BV (the Netherlands) “Submission of 
data for the evaluation of the safety and efficacy of Listex
TM
 P100 for the removal of Listeria 
monocytogenes surface contamination on raw fish“. 
2. Reply to questions posed on 17 October 2011 by the Working group to the Contact Person at 
Micreos BV (the Netherlands). Received from Micreos on 2 November 2011. 
3. Non-confidential information related to the production process of ListexTM P100. Received 
from Micreos BV on 18 November 2011. 
4. Confidential information related to the raw materials used in the production process of 
Listex
TM
 P100. Received from Micreos BV on 1 March 2012. 
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APPENDICES 
A. PUBLIC HEALTH CONCERNS ASSOCIATED WITH LISTERIOSIS AND SEAFOOD 
Listeria monocytogenes is the causative agent of human listeriosis, a potentially fatal infection (Farber 
and Peterkin, 1991). The disease is predominantly transmitted through consumption of contaminated 
foods, and is one of the major causes of death from a preventable foodborne illness with case-fatality 
rates that may exceed 30 %, especially amongst vulnerable groups. Over the past decade an increase in 
reported cases of human listeriosis has been documented (Denny and McLauchlin, 2008).  
A total of 1 601 confirmed human cases of listeriosis were reported in 2010 (EFSA and ECDC, 2012). 
This represented a 3.2 % decrease compared to 2009. The overall EU notification rate was 0.35 cases 
per 100 000 population. The overall EU notification rate of confirmed cases of listeriosis varied from 
0.33 to 0.38 cases per 100 000 population between 2006-2010 for countries reporting data for five 
consecutive years. The notification rate was highest in those aged over 65 years, covering 60.2 % of 
all reported cases, while 6.7 % of cases were detected in the age group 0-4 years with the majority of 
the cases (96.3 %, n=108) in this latter group being infants of age <1 year. The highest case fatality 
was reported for the age groups 0-5 years (22.9 %) followed by 45-64 years (19.1 %) and 65 plus 
years old (17.3 %). In total, 98 % of confirmed L. monocytogenes cases with known importation status 
were of domestic origin. The transmission route was stated for 132 (8.26 %) confirmed cases. Of 
those, 87 cases were infected with L. monocytogenes via suspected food. Of these cases, cheese was 
mentioned as the suspected vehicle for 13 cases, milk and fish for one case each, while for the 
remaining cases no information on the food source was provided. 
The BIOHAZ Panel concluded that worldwide, infection has been reported through consumption of 
contaminated food and a wide range of food types have been implicated including processed fish and 
shellfish (Brett et al., 1998; Ericsson et al., 1997; Facinelli et al., 1989; Farber et al., 2000; 
Lyytikäinen et al., 2006; Misrachi, 1991; Mitchell, 1991; Riedo et al., 1994; Tham et al., 2000). Fish 
and shellfish implicated in disease transmission included processed, ready-to-eat (RTE), able to 
support growth of this bacterium, and likely to have been contaminated at the point of processing. 
Listeria monocytogenes is widespread in the environment and commonly occurs in surface waters 
(Colburn et al., 1990; Wilkes et al., 2011), which will consequently contaminate estuarine and coastal 
waters (Beleneva, 2011; Bou-m'handi et al., 2007; Colburn et al., 1990; El-Shenawy, 2006; El 
Marrakchi et al., 2005; Hansen et al., 2006; Rodas-Suarez et al., 2006; Rorvik et al., 1995). Survival in 
seawater has been reported for a few days, and is dependent on temperature, salinity and UV light 
exposure (Bremer et al., 1998; Hansen et al., 2006; Hsu et al., 2005). 
As summarized by the BIOHAZ Panel, raw fish and smoked fish have been reported as contaminated 
by L. monocytogenes at varying rates (0-45 %), examples of which are shown in Table 1. 
Literature data on L. monocytogenes in raw, unprocessed fish report prevalence of the pathogen, but 
information on concentration is lacking; concentration data are primarily available for RTE fishery 
products. Although the prevalence of L. monocytogenes in cold-smoked fish is often high, 
concentrations of microorganisms are typically low (USDA, 2012). For instance, Eklund et al. (1995) 
found that although as many as 48 out of 61 samples of USA cold-smoked salmon contained 
L. monocytogenes, its concentration ranged from 0.3 to 34.3 colony forming units (cfu)/g with a mean 
of 6.2 cfu/g. Similarly low levels were found in Danish cold-smoked salmon, where 34 of 64 samples 
were positive, with 28 of them containing fewer than 10 cfu/g, 5 samples containing between 10 and 
100 cfu/g, and one sample containing between 100 and 1 000 cfu/g (Jorgensen and Huss, 1998). Fewer 
than 10 cfu/per gram were found in smoked finfish in USA (Jinneman et al., 1999). Furthermore, 
Johansson et al. (1999) reported that 50 % of vacuum-packed smoked fish contained <100 cfu/g. In a 
survey of smoked fish (not specified hot- or cold-smoked) on the German market, 27 samples (of 380) 
were positive for L. monocytogenes, with five samples containing less than 1 cfu/g, 14 samples 
containing between 1 and 100 cfu/g, and four samples containing between 100 and 10
4
 cfu/g; in four 
samples, levels exceeding 10
4
 cfu/g were found (Notermans et al., 1998; Teufel and Bendzulla, 1993). 
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Gombas et al. (2003) surveyed eight categories of RTE foods from retail markets in two states of the 
USA over a 14-23 month period for presence of L. monocytogenes. Total numbers of positive seafood 
salads and smoked seafood samples were 229 out of 5 090 tested, compared to 348 out of 26 615 
tested for all other six foods combined. Most samples of all foods had concentrations of the pathogen 
of less than 10 cfu/g. Counts of 10-10
6
 cfu/g were detected in 17 smoked seafood samples and 24 
samples of seven other products.  
EU legislation (Regulation (EC) No 2073/2005
8
) lays down food safety criteria for L. monocytogenes 
in RTE foods, as follows: 
 in RTE products intended for consumption by infants and for special medical purposes 
L. monocytogenes must not be present in 25 g; 
 Listeria monocytogenes must not be present at levels above 100 cfu/g during the shelf life of 
other RTE products; 
 for RTE foods that support the growth of the bacterium, L. monocytogenes may not be present 
in 25 g at the time of leaving the production plant. However, if the producer can demonstrate, 
to the satisfaction of the competent authority, that the product will not exceed the limit of 
100 cfu/g throughout shelf life this criterion does not apply; and 
 for RTE foods that support growth of L. monocytogenes, the microbiological criterion to be 
applied depends on the stage in the food chain and whether the producer has demonstrated that 
L. monocytogenes will not multiply to levels of 100 cfu/g, or above, during shelf life. 
As summarized by the BIOHAZ Panel from the EU Summary Report (EFSA and ECDC, 2012), in 
2010, 11 MSs reported data on findings of L. monocytogenes in RTE fish products. The products 
tested were mainly smoked fish, except for Romania (cooked fish). At processing level, the proportion 
of single samples of fishery products in non-compliance with the criteria (absence in 25 g) has 
increased consistently from approximately 4 % in 2007 to 9.6 % in 2010. Both in single samples 
(9.6 %) and for batch-based sampling (4.5 %), the highest level of non-compliance was observed in 
RTE fishery products when compared to the other food categories. The same observations can be 
made at retail level. The highest levels of non-compliance with the criterion of ≤100 cfu/g among 
single samples, were also observed in RTE fishery products (1 %) in 2010. For the batch-based 
sampling at retail the highest non-compliance was reported for soft and semi-soft cheeses (0.8 %) 
followed by RTE products of meat origin other than fermented sausage (0.6 %) as well as other RTE 
products (0.2 %). 
The presence of L. monocytogenes in fish was detected in eight out of 14 qualitative investigations. A 
total of 2 938 samples were tested by detection method. The Netherlands submitted near a third of 
these investigations (1 001 samples) from various types of fish (trout, mackerel, salmon, herring and 
eel) with a prevalence of 6.1 % compared to 7.0 % in 2009. High proportions of L. monocytogenes 
positive samples were reported at the processing plant by Ireland (28.3 %) and Denmark (22.2 %). 
Seven out of eleven quantitative investigations reported levels of L. monocytogenes above 100 cfu/g. 
Overall, 1.3 % of 2 607 samples tested quantitatively were found to exceed the limit of 100 cfu/g, 
compared with 0.6 % in 2009 and 0.5 % in 2008. The proportion of samples containing the bacteria at 
concentrations above the limit of 100 cfu/g ranged from 0.1 % to 18.8 %, with the highest level in 
samples of smoked fish at retail in Denmark.  
Five MSs reported investigations in other fishery products. L. monocytogenes was detected in 5.7 % of 
the 1 092 samples taken under qualitative investigations. Estonia reported the highest level of positive 
                                                     
8 Commission Regulation (EC) No 2073/2005 of 15 November 2005 on microbiological criteria for foodstuffs. OJ, L 338, 
22.12.2005, p. 1-29. 
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findings with 18.9 % positive samples taken at processing plant. Three of the five MSs also found 
L. monocytogenes at levels above 100 cfu/g with incidence ranging between 0.6 % and 7.1 %.  
Listeria monocytogenes was detected by qualitative testing in crustaceans, molluscan shellfish, and in 
other fishery products. Germany reported L. monocytogenes in 2.0 % and 3.1 % of crustaceans at retail 
and processing plant level, respectively, and Hungary reported 1.2 % of molluscan shellfish tested 
positive at retail.  
In 2010 and 2011, an EU-wide baseline survey on L. monocytogenes in RTE foods has been carried 
out targeting smoked and gravad fish, soft and semi-soft cheeses, and heat-treated meat products that 
have been handled between the heat treatment and packaging. The results of this survey will provide 
further valuable information on the occurrence of L. monocytogenes in these RTE food categories 
perceived as being at high risk regarding Listeria contamination. 
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Table 1:  Examples of rates of contamination of raw and smoked fish with L. monocytogenes 






RAW FISH (country of origin)     
Raw unfrozen aquacultured catfish, salmon, tilapia and trout (USA) Ready to cook, local and internet vendors 272 34 (13 %) Pao et al. (2008) 
Raw fish post freezing (Germany) Ready to eat, retail (sushi) 250 3 (1 %) Atanassova et al. (2008) 
Raw catfish fillets (USA) Ready to cook, factory 80 36 (45 %) Chen et al. (2010) 
Raw fish (Turkey)  Ready to cook, retail market 78 14 (18 %) Yucel and Balci (2010) 
Raw fish (Japan) Ready to eat, retail (sushi) 701 38 (5 %) Miya et al. (2010) 
Raw fish (Denmark) Ready to smoke, factory 21 5 (24 %) Wulff et al. (2006) 
Raw fish (USA) Ready to smoke, factory 102 9 (9 %) Norton et al. (2001) 
Raw salmon (Denmark) Ready to smoke, factory 30 0 Fonnesbech Vogel et al. (2001a) 
Whole raw fish (Mexico) Sea caught 66 3 (5 %) Rodas-Suarez et al. (2006) 
Whole farmed rainbow trout (Finland) Farm caught 510 15 (15 %) Miettinen and Wirtanen (2006) 
Raw and dried fish (Iceland) Ready to eat, retain and from factories 55 6 (11 %) Hartemink and Georgsson (1991) 
Raw fish (Japan) Ready to smoke, factory 94 0 Nakamura et al. (2006) 
Raw catfish fillets (USA) Ready to cook, factory 240 90 (37 %) Chou et al. (2006) 
SMOKED FISH (country of origin)     
Cold smoked fish (USA) Finished product 96 11 (12 %) Norton et al. (2001) 
Cold smoked salmon (Norway and Faroe Islands) Finished product 88 30 (34 %) Fonnesbech Vogel et al. (2001a) 
Cold smoked fish (Japan) Finished product 59 4 (7 %) Nakamura et al. (2006) 
Cold smoked salmon and trout (Denmark and Faroe Islands) Finished product 74 13 (18 %) Wulff et al. (2006) 
Cold smoked fish (USA) Finished product 300 28 (9 %) Hu et al. (2006) 
Cold smoked fish (Canada, Norway, Philippines and UK) Finished product 240 51 (21 %) Heinitz and Johnson (1998) 
Hot smoked fish (Canada, Norway, Philippines and UK) Finished product 215 19 (9 %) Heinitz and Johnson (1998) 
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B. BIOLOGY OF BACTERIOPHAGES AND THEIR USE AS ANTIBACTERIAL AGENTS 
a. Biology of bacteriophages 
Bacteriophages are viruses attacking bacteria and, as such, they are intracellular obligate 
parasites. Their infective form (the virion) is composed of a nucleic acid (usually double 
stranded DNA) surrounded by a proteinaceous coat (the capsid). Most bacteriophages possess a 
tail to allow injection of the nucleic acid into the cytoplasm, which will constitute the 
intracellular and metabolically active viral form. 
Bacteriophages are present wherever bacteria live and thus they are ubiquitous in the 
environment and in body cavities (digestive tract and vagina) where they thrive on the 
indigenous microbiota. Furthermore, they are routinely consumed with fermented foods where 
they develop at the expense of the fermentation starter bacteria; in fact, they constitute the most 
important single cause of failures in dairy fermentations. They have even been used for human 
therapy in certain eastern countries, although not currently licensed in EU and USA (Brussow, 
2005). Limited controlled clinical studies are available although no serious side effects have 
been ascribed. The few minor side effects reported (Cislo et al., 1987; Slopek et al., 1987) for 
therapeutic phages may have been due to the liberation of endotoxins from Gram-negative 
bacteria lysed in vivo by the phages. Temperate bacteriophages, however, may enhance the 
virulence of some bacterial pathogens as is explained below. 
In general, virions are able to remain in the environment for long periods of time due to their 
lack of metabolism. However, most are dependent on the presence of divalent cations and 
susceptible to temperature shifts and proteases, which are frequently produced by environmental 
microorganisms. In any case, inactivated bacteriophage particles eventually break down into 
amino acids and nucleosides and thus they do not represent a risk for the environment (Carlton 
et al., 2005). 
The encounter of a bacteriophage with its host is a random event and resulting infection relies 
on specific recognition. This implies that bacteriophages have narrow host ranges, rarely 
expanding further than the species or genus level for Gram-positive and Gram-negative bacteria, 
respectively. 
Upon infection, bacteriophages may follow a lytic or a lysogenic cycle; those that can only 
follow the lytic cycle are known as virulent while those that may choose lysogeny are called 
temperate bacteriophages. The lytic cycle ends with breakage of the host bacterial cell wall and 
liberation of the phage progeny, which may fluctuate between a few tens to a few hundred 
virions. Killing of the host may also be accomplished without phage development as a 
consequence of massive viral adsorption, which will harm the cell wall and membrane and 
produce loss of the membrane electric potential; this process is called lysis from without to 
distinguish it from the usual lysis from within. 
Temperate bacteriophages synthesize a repressor protein that silences most bacteriophage genes 
and results in abortion of the lytic cycle and in immunity to superinfection by related 
bacteriophages. This is usually followed by integration of the phage DNA into the host genome, 
which ensures transmission to the host-offspring. 
Some temperate bacteriophages harbour other genes that are also expressed during lysogeny. 
These may confer new properties to their hosts (lysogenic conversion), this being especially 
relevant for those that encode virulence factors, such as the diphtheria toxin encoded by the 
bacteriophage β of Corynebacterium diphteriae, the verocytotoxin–producing Escherichia coli 
bacteriophages, and many others. 
Bacteriophage involvement in host-acquisition of new properties also occurs through 
transduction, where bacterial DNA is transferred from cell to cell inside viral capsids. This 
process is extremely rare for bacteriophages that package unit genomes, i.e. those with cohesive 
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ends and with terminally redundant nonpermuted genomes, due to very tight recognition of the 
DNA extremes, while it is more frequent in bacteriophages that have circularly permuted 
genomes, because in this case the capsid admits as much DNA as can be accommodated, which 
is more than the unit genome and, by definition, has to have a more relaxed recognition of the 
DNA ends. 
Bacteriophage attack results in selection of bacteriophage insensitive mutants (BIMs), which 
usually have altered receptors in their cell walls. Devoted bacteriophage resistance systems have 
also been described, especially in bacteria subjected to frequent challenges, such as fermentation 
starter cultures. Among them are restriction-modification (R-M) and abortive infection (Abi), 
both of which may be plasmid encoded, thus facilitating their spread. Furthermore, the so-called 
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeat) sequences keep a memory 
of past infections in the form of short DNA sequences from the corresponding bacteriophages. 
Expression of these is believed to produce antisense RNA segments that, upon pairing with the 
mRNAs of the incoming bacteriophages, would block transcription and thus, infection. 
b. Bacteriophage contamination of animal derived products 
The presence of bacteriophages in meat is a reflection of the bacteria that contaminate the food-
animals previously and after slaughter. They appear to be especially abundant on poultry 
surfaces because the skin is retained on the carcasses and in ground beef due to the processing 
and breakage of the natural barriers to contamination (Hsu et al., 2002; Kennedy and Bitton, 
1987). The bacteriophages found are mainly those infecting enteric bacteria, especially E. coli, 
Salmonella and Campylobacter. The frequency of isolation consistently exceeds 50 % of the 






 of skin, but are 
mainly in the 10
2
 range (Hsu et al., 2002; Tsuei et al., 2007). It appears that freezing drastically 
reduces bacteriophage recovery (Atterbury et al., 2003). 
Bacteriophages specific for environmental bacteria such as Staphylococcus aureus and 
psychrotrophic microorganisms such as Pseudomonas spp. may be present as well, especially on 
meats stored at low temperature (Greer, 1983; Kennedy and Bitton, 1987). 
Isolation of bacteriophages from seafood has been reported as well, although data on this topic 
are scarcer than for meat. For example, enteric bacteriophages were recovered from water-
filtering molluscs such as mussels and oysters (Croci et al., 2000), while Pseudomonas 
bacteriophages were isolated from fish meat (Delisle and Levin, 1969). 
Finally, bacteriophages targeting the fermentation starter bacteria are abundant in dairy 
products. Their main source appears to be the milk or the bacteriophages that are endemic in the 
factory rather than the starter inocula (Madera et al., 2003). 
c. Bacteriophages as antibacterial agents in foods 
Bacteriophages used in food-decontamination have to possess at least the following properties: 
(i) be virulent to avoid lysogenization leading to survival and lysogenic conversion of the 
infected host; (ii) have unit genome packaging to minimize transduction; (iii) cover a wide 
range of susceptible bacteria, which in practical terms means many strains within a single 
species or, at most, several species of a genus; (iv) generate numerous progeny; and, (v) have a 
short lytic cycle to allow multiple rounds of infection-host lysis (EFSA Panel on Biological 
Hazards (BIOHAZ), 2009). 
On the other hand, bacteriophages are obligate parasites and thus their development depends on 
the growth conditions of their hosts. The problem may then arise when the bacteria are in the 
stationary phase or growing very slowly, which may be the predominant conditions in foods due 
to the preservation procedures: low temperatures, low water activity whether caused by salt or 
other means, etc. It is, however, believed that, in the environment, bacteria are in a state similar 
to stationary phase most of the time and this does not preclude high bacteriophage abundance in 
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natural ecosystems. In fact, bacteriophage replication, albeit at a reduced rate, has been observed 
on stationary phase E. coli and P. aeruginosa cells (Schrader et al., 1997). 
Another consideration to bear in mind is the relative host-bacteriophage concentration and the 
possibility for the latter to diffuse on the surface of solid food during the treatment. Concerning 
this, two approaches for bacteriophage usage are possible (EFSA, 2009): 
Passive treatment. Bacteriohages are added in sufficient quantity to cover the whole surface 
and overwhelm all target bacteria by primary infection and, ideally, by lysis from without. This 
is the technique to use in case of low-level bacterial contamination and on relatively dry food 
surfaces that will not allow significant diffusion of progeny bacteriophages. Two advantages of 
lysis from without are that no bacteriophage development would be necessary for cell killing 
and that the cytoplasm bacteriophage resistance mechanisms (R-M, Abi, CRISPR) would not be 
an issue.  
Active treatment. Elimination of bacteria will rely on successive rounds of development-lysis. 
Success will depend on a relatively high host concentration and the possibility for the 
bacteriophage to spread on the material, which will be very much influenced by the moisture 
and the presence of inert cells on which progeny bacteriophages might become adsorbed. The 
problem of this procedure may be to define what is „a relatively high host concentration‟. There 
are several mathematical models aimed at defining a threshold for efficacy, but their 
conclusions differ by several orders of magnitude (Kasman et al., 2002; Obeso et al., 2010; 
Payne and Jansen, 2001; Wiggins and Alexander, 1985). This might be due to the combinations 
of bacteriophage-host used, to the characteristics of the foods treated or to the assumptions 
made for modelling. In practice, the treatment efficacy parameters have to be determined 
experimentally on a case-by-case basis. 
Control of undesirable bacteria by bacteriophages has been assayed in most types of foods of 
animal origin, poultry being the most widely tested. In this case, most studies addressed 
Salmonella and Campylobacter, the main concerns in these meats (Goode et al., 2003; Higgins 
et al., 2005), while those performed on beef and pork products challenged mostly E. coli O157, 
L. monocytogenes and the psychrotrophe Brochothrix thermosphacta (Abuladze et al., 2008; 
Anany et al., 2011; Zhang et al., 2010). Work on sea-food involved L. monocytogenes almost 
exclusively (Guenther et al., 2009; Soni and Nannapaneni, 2010; Soni et al., 2010) and those on 
dairy products focused on L. monocytogenes and staphylococci (Carlton et al., 2005; Garcia et 
al., 2007; Schellekens et al., 2007). The overall conclusion might be that frequently the bacterial 
titres are reduced significantly and even go below detectable levels, especially when 
concentrated bacteriophage preparations are used and when the treatment is combined with nisin 
or proceeds at room temperature, instead of under the usual refrigerated conditions (Bigwood et 
al., 2008; Dykes and Moorhead, 2002; Garcia et al., 2010). In some cases, bacterial recovery 
was detected upon prolonged incubation. These survivors were usually not bacteriophage 
resistant. This suggests that bacteriophages may become adsorbed to the food matrix soon after 
application, although this does not necessarily mean inactivation, because they can be washed 
from it and still produce plaques of lysis (Guenther et al., 2009). This behaviour variability 
impedes the definition of bacteriophages as processing aids or as additives, when applied to 
foods for decontamination (EFSA, 2009). 
Finally, in the 2009 EFSA update on the maintenance of the list of Qualified Presumption of 
Safety (QPS) microorganisms intentionally added to food or feed (EFSA Panel on Biological 
Hazards (BIOHAZ), 2009) is concluded that “bacteriophages cannot be included on the QPS 
list” but rather have to be allocated to a case by case analysis before authorization to be used on 
foods is granted and this for the following reasons: i) impossibility to place them to precise 
taxonomical units (genera and species), and ii) impossibility to know a priori whether a 
particular bacteriophage is strictly virulent, does not harbor potentially harming genes and does 
not have the possibility to transduce bacterial DNA between hosts.  
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C. FISH PROCESSING LINES AND LISTERIA MONOCYTOGENES CONTAMINATION 
The following material is summarized by the BIOHAZ Panel. L. monocytogenes can be present 
in both fresh and marine water, with the highest prevalence in coastal areas and in polluted 
waters (Ben Embarek, 1994). In fish, L. monocytogenes is commonly found on surfaces of skin, 
gills, heads and slime, and the contamination of fish most likely depends on the presence of the 
bacteria in the surrounding waters. Hence, it was suggested that raw fish is the primary source 
of contamination for RTE fish (Eklund et al., 1995), but this was concluded without molecular 
tracing of the isolates.  
In contrast, a number of other studies using molecular typing techniques have suggested that 
raw fish is not the major source of final product contamination; rather, contamination occurs 
primarily during processing (Fonnesbech Vogel et al., 2001a; Fonnesbech Vogel et al., 2001b; 
Norton et al., 2001). Fish processing is very diverse and includes a number of steps that vary 
with types of fish and types of intended product. For illustration purposes, examples of generic 
flow diagrams of processing of live fish, cooled/frozen fish and cold-smoked fish are 
summarised in Figures 1, 2 and 3, demonstrating the complexity of these processes. It is not 
possible to outline in detail all possible types of production practices and their variations that are 
used for different fish products in different countries, because they are numerous and complex 
as they are both product- and producer-specific. As concluded by the BIOHAZ Panel, the 
complexity of the fish processing procedures makes possible repeated contamination of the 
product with L. monocytogenes via various routes, which makes control of the pathogen 
complex and requiring application of a range of control measures at different points in the 
process (e.g. raw materials-, environment-, staff-, equipment- and product-focused). 
Listeria monocytogenes strains that contaminate fish are often recovered from processing 
equipment such as mechanical saws, brining, slicing, dicing, freezing, and packaging machines 
and conveyors. These machines are therefore considered essential niches of the bacteria and 
important sites of product contamination (Aguado et al., 2001; Autio et al., 1999; Autio et al., 
2003; Lunden et al., 2003a; Lunden et al., 2003b; Miettinen et al., 1999; Norton et al., 2001; 
Ojeniyi et al., 2000; Rorvik, 2000; Rorvik et al., 1995). Such equipment often has narrow 
openings and dead-end areas making its dismantling for efficient cleaning and sanitation 
difficult. In cold smoked fish processing plants, the most contaminated sites are the brining and 
post-brining areas, and during production the brine solutions become contaminated with 
L. monocytogenes originating from brining machines (Autio et al., 1999; Autio et al., 2003). 
Airborne bacterial contamination is also possible in the food processing environment in general 
(Bjorkroth and Korkeala, 1997; Rahkio and Korkeala, 1997), but published research does not 
indicate air-mediated contamination as of major importance in L. monocytogenes contamination 
of processed fish. 
Furthermore, the employees may play some role in the spreading of L. monocytogenes 
contamination, but the extent of their contribution to processed fish contamination still remains 
unclear. The gloves of fish handlers were found contaminated, but most likely become 
contaminated when the workers handle the fish, rather than the gloves themselves being the 
source of contamination (Autio et al., 1999; Autio et al., 2003). 
A letter by Professor L. Gram
9
 included in the application dossier (reference letter d.d. 27 Oct 
2010), states that, according to their studies in the Danish smoked fish industry, contamination 
of the product (smoked salmon) predominantly takes place during processing (slicing), after 
salting and smoking. The raw fish does sporadically harbour L. monocytogenes and the raw fish 
processing area often has a relatively high occurrence of L. monocytogenes, but the molecular 
subtypes on raw fish are in most processing plants different from the subtypes encountered 
                                                     
9  L. Gram is Professor at the Division of Industrial Food Research, Technical University of Denmark (DTU-FOOD), 
Kgs. Lynby, Denmark. 
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during processing and on the final product. The original contamination sources of 
L. monocytogenes are not known but it likely enters from almost any outside source (raw fish, 
trucks, boots, boxes). Reducing this introduction could potentially limit the contamination of the 
final product. It is further stated in the letter that: procedures (preservation) that prevent growth 
in the product are essential for safety improvement; processes that eliminate the organism at the 
end of production would be of interest; and irrespective of such measures, it is of great 
importance that continued efforts are made to reduce contamination level and prevalence at all 
steps in production.  
Overall, even though fish product contamination appears to be clearly associated with 
processing, the initial origin of processing plant contamination remains undetermined (Autio et 
al., 1999; Autio et al., 2003). L. monocytogenes may be introduced into the processing 
environment and subsequently onto the product through a number of routes, including via 
incoming raw materials (e.g. fish, water, ice), other materials (e.g. packaging, additives), 
biofilms on equipment and other surfaces, and to a lesser extent employees handling the product 
along the production line. Contributing sources may also vary between plants. This is indirectly 
shown in some published studies. For example, the overall incidence of L. monocytogenes in 
fish processing plants varied from 5.9 % to 22.1 %; roughly >3-fold (Gudbjornsdottir et al., 
2004). Also, a Danish study indicated great plant-to-plant variation in contamination rate, thus 
from some plants all product samples were positive whereas other plants produced products 
where L. monocytogenes was not detected (Jorgensen and Huss, 1998). A similar conclusion 
was reached by Norton et al. (2001) who visited five United States smoke houses over a 6-
month period. Using ribotyping, the authors found that each smoke house harbored its own 
specific ribotype(s) of L. monocytogenes. 
It seems that L. monocytogenes contamination of processed fish cannot be attributed to a single 
production step; in such a case a single decontamination treatment could have been applied in 
order to solve the problem. Rather, because the contamination can occur at multiple steps, re-
contamination of the fish post-decontamination during the production process may also occur, 
which would diminish or negate the anti-listerial effects achieved with the single 
decontamination treatment previously applied. Hence, any anti-listerial decontamination 
treatment(s) would need to be specified and justified in terms of the production-processing step 
or steps where its application(s) is proposed. Since the length of time that the bacteriophage 
remains active and the levels of L. monocytogenes contamination to be inactivated were not 
sufficiently documented, the overall efficacy of the Listex™ P100 decontamination cannot be 
assessed throughout the food chain. Thus, the impact of treating raw fish with P100 as early in 
processing as possible on the contamination of the final product needs to be established. 
Processors would need specific guidance for proper implementation of the treatment. 
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Figure 1:  Flow diagram of the production of cooled or frozen fish from live fish (Adapted 
from CAC (2005)) 
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Figure 2:  Flow diagram of fish fillet and minced fish (mechanically recovered fish flesh) 
production (Adapted from CAC (2005)) 
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Figure 3:  Flow diagram of hot smoking, cold smoking and by regenerated smoke preparation 
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GLOSSARY AND ABBREVIATIONS 
 
Abi Abortive infection 
BIM Bacteriophage insensitive mutant 
cfu Colony forming unit 
CRISPR Clustered Regularly Interspaced Short Palindromic Repeat 
GHP Good Hygienic Practices 
GLP Good Laboratory Practices 
GRAS Generally Regarded As Safe 
HACCP Hazard Analysis Critical Control Point 
MAP Modified Atmosphere Packaging 
pfu Plaque-forming units 
QAC Quaternary ammonium compound 
QPS Qualified Presumption of Safety 
PCR Polymerase chain reaction 
R-M Restriction-modification 
RTE Ready-to-eat 
vgc Virulence gene cluster 
 
